Q2KJC1
PR
Gene name |
CDC5L |
Protein name |
Cell division cycle 5-like protein |
Names |
Cdc5-like protein |
Species |
Bos taurus (Bovine) |
KEGG Pathway |
bta:767817 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q2KJC1
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q2KJC1-F1 | Predicted | AlphaFoldDB |
75 variants for Q2KJC1
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs460332606 | 7 | K>N | No | EVA | |
| rs445747130 | 14 | T>P | No | EVA | |
| rs445747130 | 14 | T>S | No | EVA | |
| rs465785646 | 27 | G>V | No | EVA | |
| rs434512442 | 34 | I>L | No | EVA | |
| rs451320094 | 38 | L>R | No | EVA | |
| rs471262456 | 42 | S>T | No | EVA | |
| rs455021539 | 51 | Y>F | No | EVA | |
| rs444564591 | 51 | Y>H | No | EVA | |
| rs461220586 | 114 | E>K | No | EVA | |
| rs454120314 | 117 | T>S | No | EVA | |
| rs476304133 | 162 | T>P | No | EVA | |
| rs441630654 | 169 | R>S | No | EVA | |
| rs461573407 | 170 | K>E | No | EVA | |
| rs441484550 | 175 | Q>E | No | EVA | |
| rs458251282 | 176 | L>Q | No | EVA | |
| rs478454480 | 178 | E>* | No | EVA | |
| rs465785584 | 185 | L>F | No | EVA | |
| rs479381639 | 186 | Q>R | No | EVA | |
| rs444949550 | 190 | E>G | No | EVA | |
| rs436798399 | 195 | G>R | No | EVA | |
| rs468114149 | 196 | I>L | No | EVA | |
| rs436664128 | 196 | I>T | No | EVA | |
| rs473616268 | 201 | K>T | No | EVA | |
| rs438938407 | 202 | R>G | No | EVA | |
| rs452590740 | 203 | K>E | No | EVA | |
| rs475901131 | 204 | K>T | No | EVA | |
| rs444471648 | 216 | F>L | No | EVA | |
| rs461160524 | 227 | T>S | No | EVA | |
| rs480357127 | 228 | S>Y | No | EVA | |
| rs442694628 | 239 | F>L | No | EVA | |
| rs479660262 | 241 | K>* | No | EVA | |
| rs444952152 | 241 | K>M | No | EVA | |
| rs465108176 | 243 | R>* | No | EVA | |
| rs481969184 | 244 | Q>P | No | EVA | |
| rs450490141 | 245 | Q>R | No | EVA | |
| rs467349432 | 253 | S>C | No | EVA | |
| rs444294280 | 280 | L>P | No | EVA | |
| rs454702387 | 281 | Q>* | No | EVA | |
| rs474737767 | 298 | P>S | No | EVA | |
| rs440151037 | 301 | Q>H | No | EVA | |
| rs433811555 | 360 | D>V | No | EVA | |
| rs454780581 | 395 | V>L | No | EVA | |
| rs438006585 | 421 | E>D | No | EVA | |
| rs473938821 | 427 | S>G | No | EVA | |
| rs442707643 | 427 | S>N | No | EVA | |
| rs453150310 | 428 | G>E | No | EVA | |
| rs438541290 | 436 | N>T | No | EVA | |
| rs458670010 | 446 | D>A | No | EVA | |
| rs481910850 | 447 | K>Q | No | EVA | |
| rs444071818 | 448 | L>F | No | EVA | |
| rs460926229 | 449 | N>K | No | EVA | |
| rs481024149 | 453 | E>D | No | EVA | |
| rs447103435 | 454 | D>H | No | EVA | |
| rs477698552 | 456 | M>I | No | EVA | |
| rs467250221 | 456 | M>R | No | EVA | |
| rs446202257 | 465 | V>A | No | EVA | |
| rs442843922 | 477 | R>C | No | EVA | |
| rs461403527 | 498 | A>V | No | EVA | |
| rs476564562 | 499 | E>* | No | EVA | |
| rs445970795 | 515 | A>D | No | EVA | |
| rs451908888 | 524 | A>G | No | EVA | |
| rs385208935 | 575 | I>V | No | EVA | |
| rs449788476 | 590 | H>P | No | EVA | |
| rs463314878 | 606 | G>S | No | EVA | |
| rs480358461 | 628 | E>D | No | EVA | |
| rs432194342 | 674 | Q>K | No | EVA | |
| rs439295915 | 697 | E>* | No | EVA | |
| rs432379899 | 729 | M>I | No | EVA | |
| rs446941278 | 729 | M>L | No | EVA | |
| rs466899608 | 729 | M>T | No | EVA | |
| rs447616732 | 761 | S>F | No | EVA | |
| rs467707069 | 784 | L>R | No | EVA | |
| rs481332254 | 788 | Y>D | No | EVA | |
| rs466772113 | 800 | A>S | No | EVA |
No associated diseases with Q2KJC1
6 regional properties for Q2KJC1
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | SANT/Myb domain | 3 - 56 | IPR001005-1 |
| domain | SANT/Myb domain | 55 - 106 | IPR001005-2 |
| domain | Myb domain | 1 - 58 | IPR017930-1 |
| domain | Myb domain | 59 - 108 | IPR017930-2 |
| domain | Pre-mRNA splicing factor component Cdc5p/Cef1, C-terminal | 404 - 655 | IPR021786 |
| domain | Pre-mRNA splicing factor component CDC5L/Cef1, second SANT/myb-like domain | 56 - 107 | IPR047240 |
7 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| DNA replication factor A complex | A conserved heterotrimeric complex that binds nonspecifically to single-stranded DNA and is required for multiple processes in eukaryotic DNA metabolism, including DNA replication, DNA repair, and recombination. In all eukaryotic organisms examined the complex is composed of subunits of approximately 70, 30, and 14 kDa. |
| nuclear speck | A discrete extra-nucleolar subnuclear domain, 20-50 in number, in which splicing factors are seen to be localized by immunofluorescence microscopy. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| Prp19 complex | A protein complex consisting of Prp19 and associated proteins that is involved in the transition from the precatalytic spliceosome to the activated form that catalyzes step 1 of splicing, and which remains associated with the spliceosome through the second catalytic step. It is widely conserved, found in both yeast and mammals, though the exact composition varies. In S. cerevisiae, it contains Prp19p, Ntc20p, Snt309p, Isy1p, Syf2p, Cwc2p, Prp46p, Clf1p, Cef1p, and Syf1p. |
| spliceosomal complex | Any of a series of ribonucleoprotein complexes that contain snRNA(s) and small nuclear ribonucleoproteins (snRNPs), and are formed sequentially during the spliceosomal splicing of one or more substrate RNAs, and which also contain the RNA substrate(s) from the initial target RNAs of splicing, the splicing intermediate RNA(s), to the final RNA products. During cis-splicing, the initial target RNA is a single, contiguous RNA transcript, whether mRNA, snoRNA, etc., and the released products are a spliced RNA and an excised intron, generally as a lariat structure. During trans-splicing, there are two initial substrate RNAs, the spliced leader RNA and a pre-mRNA. |
| U2-type catalytic step 2 spliceosome | A spliceosomal complex that contains the U2, U5 and U6 snRNPs bound to a splicing intermediate in which the first catalytic cleavage of the 5' splice site has occurred. The precise subunit composition differs significantly from that of the catalytic step 1, or activated, spliceosome, and includes many proteins in addition to those found in the U2, U5 and U6 snRNPs. |
6 GO annotations of molecular function
| Name | Definition |
|---|---|
| DNA-binding transcription activator activity, RNA polymerase II-specific | A DNA-binding transcription factor activity that activates or increases transcription of specific gene sets transcribed by RNA polymerase II. |
| DNA-binding transcription factor activity, RNA polymerase II-specific | A DNA-binding transcription factor activity that modulates the transcription of specific gene sets transcribed by RNA polymerase II. |
| identical protein binding | Binding to an identical protein or proteins. |
| RNA binding | Binding to an RNA molecule or a portion thereof. |
| RNA polymerase II transcription regulatory region sequence-specific DNA binding | Binding to a specific sequence of DNA that is part of a regulatory region that controls the transcription of a gene or cistron by RNA polymerase II. |
| WD40-repeat domain binding | Binding to a WD40 repeat domain of a protein. The WD40 repeat is a short structural motif of approximately 40 amino acids, often terminating in a tryptophan-aspartic acid (W-D) dipeptide. Several of these repeats are combined to form a type of protein domain called the WD domain. |
5 GO annotations of biological process
| Name | Definition |
|---|---|
| cell cycle | The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division. |
| DNA damage checkpoint signaling | A signal transduction process that contributes to a DNA damage checkpoint. |
| DNA repair | The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway. |
| mRNA splicing, via spliceosome | The joining together of exons from one or more primary transcripts of messenger RNA (mRNA) and the excision of intron sequences, via a spliceosomal mechanism, so that mRNA consisting only of the joined exons is produced. |
| regulation of transcription by RNA polymerase II | Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase II. |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MPRIMIKGGV | WRNTEDEILK | AAVMKYGKNQ | WSRIASLLHR | KSAKQCKARW | YEWLDPSIKK |
| 70 | 80 | 90 | 100 | 110 | 120 |
| TEWSREEEEK | LLHLAKLMPT | QWRTIAPIIG | RTAAQCLEHY | EFLLDKAAQR | DNEEETTDDP |
| 130 | 140 | 150 | 160 | 170 | 180 |
| RKLKPGEIDP | NPETKPARPD | PIDMDEDELE | MLSEARARLA | NTQGKKAKRK | AREKQLEEAR |
| 190 | 200 | 210 | 220 | 230 | 240 |
| RLAALQKRRE | LRAAGIEIQK | KRKKKRGVDY | NAEIPFEKKP | ALGFYDTSEE | NYQTLDADFR |
| 250 | 260 | 270 | 280 | 290 | 300 |
| KLRQQDLDGE | LRSEKEGRDR | KKDKQHLKRK | KESDLPSAIL | QTSGVSEFTK | KRSKLVLPAP |
| 310 | 320 | 330 | 340 | 350 | 360 |
| QISDAELQEV | VKVGQASEIA | RQTAEESGIT | NSASSTLLSE | YNVTNNSIAL | RTPRTPASQD |
| 370 | 380 | 390 | 400 | 410 | 420 |
| RILQEAQNLM | ALTNVDTPLK | GGLNTPLHES | DFSGVTPQRQ | VVQTPNTVLS | TPFRTPSHGS |
| 430 | 440 | 450 | 460 | 470 | 480 |
| EGLTPRSGTT | PKPVINSTPG | RTPLRDKLNI | NPEDGMADYS | DPSYVKQMER | ESREHLRLGL |
| 490 | 500 | 510 | 520 | 530 | 540 |
| LGLPAPKNDF | EIVLPENAEK | ELEEREIDDT | YIEDAADVDA | RKQAIRDAER | VKEMKRMHKA |
| 550 | 560 | 570 | 580 | 590 | 600 |
| VQKDLPRPSE | VNETILRPLN | VEPPLTDLQK | SEELIKKEMI | TMLHYDLLHH | PYEPSGNKKG |
| 610 | 620 | 630 | 640 | 650 | 660 |
| KTVGFGTNNA | EHIAYLEHNP | YEKFSKEELK | KAQDVLVQEM | EVVKQGMSHG | ELSSEAYNQV |
| 670 | 680 | 690 | 700 | 710 | 720 |
| WEECYSQVLY | LPGQSRYTRA | NLASKKDRIE | SLEKRLEINR | GHMTTEAKRA | AKMEKKMKIL |
| 730 | 740 | 750 | 760 | 770 | 780 |
| LGGYQSRAMG | LMKQLNDLWD | QIEQAYLELR | TFEELKKHED | SAIPRRLECL | KEDVQRQQER |
| 790 | 800 | ||||
| EKELQHRYAD | LLLEKETLKA | KF |